Elutia Inc (ELUT) Stock Score, Valuation & Financial Research
Elutia Inc is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 63/100.
Quick answer for ELUT
Elutia Inc currently has a Wall Street Score of 63/100. The stored market price is $0.81. Its financial score is 8/100. Its valuation score is 100/100. The latest WSS change is +0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Elutia Inc does
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damag
ELUT financial snapshot
- Wall Street Score:
- 63/100
- Current price:
- $0.81
- Market capitalization:
- $35.8M
- Revenue:
- $12.1M
- Net income:
- $51.8M
- Free cash flow:
- $-46.7M
- Cash:
- $19.9M
- Total debt:
- $10.8M
- EPS:
- 1.30
- P/E ratio:
- 0.6x
- Financial score:
- 8/100
- Valuation score:
- 100/100
- Revenue score:
- 38/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $-46.7M, showing cash burn in the current stored period.
- The balance sheet shows $19.9M of cash versus $10.8M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.1 points: ELUT increased 0.1 points because overall fundamentals improved.
What the numbers mean
Its current valuation score is 100/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 8/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-07.
How to research ELUT
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.